3 Stocks Dragging The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.1%) at 16,756 as of Friday, June 13, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,558 issues advancing vs. 1,369 declining with 183 unchanged.

The Drugs industry currently sits down 0.4% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the industry include United Therapeutics ( UTHR), down 4.0%, Novo Nordisk A/S ( NVO), down 1.6%, Biomarin Pharmaceutical ( BMRN), down 1.6%, Grifols ( GRFS), down 1.1% and Vertex Pharmaceuticals ( VRTX), down 0.9%. Top gainers within the industry include Mylan ( MYL), up 1.0%, Actavis ( ACT), up 0.8% and Forest Laboratories ( FRX), up 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Alexion Pharmaceuticals ( ALXN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Alexion Pharmaceuticals is down $2.29 (-1.4%) to $163.68 on light volume. Thus far, 515,916 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $162.63-$166.68 after having opened the day at $166.10 as compared to the previous trading day's close of $165.97.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $33.1 billion and is part of the health care sector. Shares are up 24.9% year-to-date as of the close of trading on Thursday. Currently there are 13 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, increase in net income and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Alexion Could Target Sage, Ra Pharma: Analyst

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk